Responses of CLL cells to purine analogs with cyclophosphamide

Zofia Kilia¿ska

ISBN 10: 3659111635 / ISBN 13: 9783659111631

Edité par LAP LAMBERT Academic Publishing Feb 2014, 2014

A propos de cet article

Neuware -Our findings demonstrate the need of ex vivo chronic lymphocytic leukemia cell (CLL) treatment before the application of drugs to select the most efficient manner of the patient¿s therapy. The obtained results confirm the link between the outcomes of the research done under ex vivo and in vivo conditions and underline the usefulness of ex vivo studies in the individual choice of CLL treatment. Our observations provide a base for further studies on the relationship between the in vivo clinical responses of patients and ex vivo pro-apoptotic activity, and the cytotoxicity of drugs against leukemic cells. Their validation by a study comprising a much larger group of patients is needed.Books on Demand GmbH, Überseering 33, 22297 Hamburg 60 pp. Englisch.

N° de réf. du vendeur 9783659111631

Détails bibliographiques

• Titre: Responses of CLL cells to purine analogs with cyclophosphamide
• Éditeur: LAP LAMBERT Academic Publishing Feb 2014
• Date de parution: 2014
• Langue: anglais
• ISBN à 10 chiffres: 3659111635
• ISBN à 13 chiffres: 9783659111631
• Reliure: Taschenbuch
• État de l'article: Neu
• Dimensions: 220 L x 150 H x 4 P (en millimètres) 220 millimètres de largeur par 150 millimètres de hauteur par 4 millimètres de profondeur
• Poids: 107 grammes

A propos de ce titre

Synopsis

Our findings demonstrate the need of ex vivo chronic lymphocytic leukemia cell (CLL) treatment before the application of drugs to select the most efficient manner of the patient’s therapy. The obtained results confirm the link between the outcomes of the research done under ex vivo and in vivo conditions and underline the usefulness of ex vivo studies in the individual choice of CLL treatment. Our observations provide a base for further studies on the relationship between the in vivo clinical responses of patients and ex vivo pro-apoptotic activity, and the cytotoxicity of drugs against leukemic cells. Their validation by a study comprising a much larger group of patients is needed.